{
    "nct_id": "NCT03055598",
    "official_title": "Effect of Auryxia on ESA Utilization in ESRD Patients With High Ferritin & Low Transferrin Saturation: A Pilot Project",
    "inclusion_criteria": "1. Signed informed consent prior to any study specific procedures\n2. Male and females aged 18 years and older\n3. In the Investigator's opinion, expected to survive at least 3 months\n4. Able to tolerate phosphate binders\n5. ESRD and on dialysis for over 90 days\n6. Deemed stable by Investigator\n7. Serum Ferritin >1000 ng/ml (measured as average of at least 2 values in the last 3 months +/- 10 days)\n8. TSAT < 30% ( measured as average of at least 2 values in the last 30 days, +/- 10 days)\n9. Hemoglobin < 12g/dl (measured as average of at least 2 values in the last 30 days, +/- 10 days)\n10. Currently on ESA for at least 1 month, as per dialysis unit protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Inability or refusal to give informed consent\n2. Subject unwilling to take study medication for 3 months\n3. Currently on IV Iron\n4. Currently on Auryxia as phosphate binder (or received in prior 3 months)\n5. Deemed non-compliant by care team for dialysis or medication\n6. Active gastrointestinal bleed\n7. Inflammatory bowel disease\n8. History of malignancy within 5 years before screening (exceptions: squamous and basal cell carcinomas of the skin and carcinoma of the cervix in situ, or a malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence).\n9. Known allergy to oral iron products\n10. Pregnant\n11. Breastfeeding",
    "miscellaneous_criteria": ""
}